A clinical review of echinocandins in pediatric patients

Annals of Pharmacotherapy

Volumn 44, Issue 1, 2010, Pages 166-177

  VandenBussche, Heather L ^a   Van Loo, Dean A ^a  

^a FERRIS STATE UNIVERSITY   (United States)

Author keywords

Anidulafungin; Caspofungin; Echinocandins; Micafungin; Pediatrics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; NIFEDIPINE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ABDOMINAL ABSCESS; AREA UNDER THE CURVE; ASPERGILLOSIS; BILIRUBIN BLOOD LEVEL; CANDIDEMIA; CANDIDIASIS; CHEST INFECTION; CHILL; DIARRHEA; DISTRIBUTION VOLUME; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEVER; FKS1 GENE; FKS2 GENE; FUNGEMIA; GENE; GENE MUTATION; HEADACHE; HEMOPTYSIS; HUMAN; HYPOKALEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INVASIVE CANDIDIASIS; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MENINGOENCEPHALITIS; MORTALITY; MYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERITONITIS; PHARMACODYNAMICS; PHLEBITIS; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RASH; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION; VEIN THROMBOSIS; VOMITING;

ANTIFUNGAL AGENTS; CHILD; ECHINOCANDINS; HUMANS; MYCOSES;

EID: 74549142906     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M139     Document Type: Review

References (64)

1. Product information. Cancidas (caspofungin). Whitehouse Station, NJ: Merck & Co., July 2009.
2. Product information. Eraxis (anidulafungin). New York, NY: Pfizer Inc., June 2009.
3. Product information. Mycamine (micafungin). Deerfield, IL: Astellas Pharma US, January 2008.
4. Sobel JD, Revankar SG. Echinocandins - first-choice or first-line therapy for invasive candidiasis? N Engl J Med 2007;356:2525-6.
5. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001;10:269-80. DOI 10.1517/13543784.10.2.269
6. Mazur P, Morin N, Baginsky W, et al. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol 1995;15:5671-81.
7. Douglas CM, D'Ippolito JA, Shei GJ, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997;41:2471-9.
8. Denning DW. Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997;40:611-4.
9. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008;46:150-6. Epub 23 Nov 2007. DOI 10.1128/JCM.01901-07
10. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008;52:321-8. Epub 17 Oct 2007. DOI 10.1128/AAC.00699-07
11. Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007;51:1616-20. Epub 20 Feb 2007. DOI 10.1128/AAC.00105-07
12. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007;51:2253-6. Epub 9 Apr 2007. DOI 10.1128/AAC.01536-06
13. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol 2006;44:3533-8. DOI 10.1128/JCM.00872-06
14. Ikeda F, Saika T, Sato Y, et al. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med Mycol 2009;47:145-8. Epub 1 Aug 2008. DOI 10.1080/13693780802262123
15. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000;182:1791-5. DOI 10.1086/317614
16. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51:2587-90. Epub 25 Apr 2007. DOI 10.1128/AAC.00452-07
17. Zeng J, Kamei K, Zheng Y, Nishimura K. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents. Nippon Ishinkin Gakkai Zasshi 2004;45:101-4.
18. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.
19. Ito M, Nozu R, Kuramoc T, et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000;44:2259-62.
20. Cao C, Liu W, Li R, Wan Z, Qiao J. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei. J Antimicrob Chemother 2009;63:340-2. Epub 5 Dec 2008. DOI 10.1093/jac/dkn494
21. Ruiz-Cendoya M, Rodriguez MM, Marine M, Pastor FJ, Guarro J. In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi. Int J Antimicrob Agents 2008;32:418-20. DOI 10.1016/j.ijantimicag.2008.05.015
22. Shalit I, Shadkchan Y, Mircus G, Osherov N. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. Med Mycol 2009;47:457-62.
23. Marine M, Serena C, Pastor J, Quindos G, Carrillo AJ, Guarro J. In vitro activity of micafungin combined with itraconazole against Candida spp. Int J Antimicrob Agents 2007;30:463-5. Epub 19 Aug 2007. DOI 10.1016/j.ijantimicag.2007.06.022
24. Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:1187-92.
25. Andes D, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008;52:539-50. Epub 12 Dec 2007. DOI 10.1128/AAC.01061-07
26. Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008;52:3497-503. Epub 16 July 2008. DOI 10.1128/AAC.00478-08
27. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005;49:5058-68. DOI 10.1128/AAC.49.12. 5058-5068.2005
28. Venisse N, Gregoire N, Marliat M, Couet W. Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans. Antimicrob Agents Chemother 2008;52:937-43. Epub 9 Jan 2008. DOI 10.1128/AAC.01030-07
29. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother 2007;51:881-7. Epub 6 Dec 2006. DOI 10.1128/AAC.01160-06
30. Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004;190:1464-71. Epub 10 Sep 2004. DOI 10.1086/424465
31. Cota JM, Grabinski JL, Talbert RL, et al. Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Antimicrob Agents Chemother 2008;52:1144-6. Epub 19 Dec 2007. DOI 10.1128/AAC.01542-07
32. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 2003;48:225-35.
33. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002;46:3634-6.
34. Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2339-44.
35. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49:4536-45. DOI 10.1128/AAC.49.11.4536-4545.2005
36. Neely M, Jafri HS, Seibel N, et al. The pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009;53:1450-6.
37. Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009;53:869-75. Epub 17 Dec 2008. DOI 10.1128/AAC.00868-08
38. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317-24. DOI 10.1128/AAC.49.8. 3317-3324.2005
39. Tabata K, Katashima M, Kawamura A, Tanigawara Y, Sunagawa K. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull 2006;29:1706-11.
40. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25:1110-5. DOI 10.1097/01.inf.0000245103.07614.e1
41. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008;197:163-71. DOI 10.1086/524063
42. Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007;51:3714-9. Epub 20 Jul 2007. DOI 10.1128/AAC.00398-07
43. Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother 2008;52:2673-6. Epub 30 Apr 2008. DOI 10.1128/AAC.01596-07
44. Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50:632-8. DOI 10.1128/AAC.50.2.632-638.2006
45. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16. DOI 10.1086/422312
46. Koo A, Sung L, Allen U, et al. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children. Pediatr Infect Dis J 2007;26:854-6. DOI 10.1097/INF.0b013e318067b4d1
47. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23:1093-7.
48. Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005;25:770-7. Epub 14 Oct 2005. DOI 10.1038/sj.jp.7211380
49. Merlin E, Galambrun C, Ribaud P, et al. Efficacy and safety of caspofungin therapy in children with invasive fungal infections. Pediatr Infect Dis J 2006;25:1186-8. DOI 10.1097/01.inf.0000246844.42159.a0
50. Groll AH, Attarbasc A, Schuster FR, et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother 2006;57:527-35. Epub 25 Jan 2006. DOI 10.1093/jac/dkl009
51. Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003;22:747-9. 52. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008;27:820-6. DOI 10.1097/INF.0b013e31817275e6
52. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-61. DOI 10.1007/s10096-005-0024-8
53. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337-49. DOI 10.1016/j.jinf.2006.03.003
54. Cesaro S, Giacchino M, Locatelli F, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007;7:28. Epub 20 Apr 2007. DOI 10.1186/1471-2334-7-28
55. Cesaro S, Toffolutti T, Messina C, et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004;73:50-5. DOI 10.1111/j.1600-0609.2004.00254.x
56. Yalaz M, Akisu M, Hilmioglu S, Calkavur S, Cakmak B, Kultursay N. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses 2006;49:242-5. DOI 10.1111/j.1439-0507.2006.01220.x
57. Mrowczynski W, Wojtalik M. Caspofungin for Candida endocarditis. Pediatr Infect Dis J 2004;23:376.
58. Wertz KK, Pretzlaff RK. Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med 2004;5:181-3.
59. Castagnola E, Machetti M, Cappelli B, et al. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant. Clin Microbiol Infect 2004;10:255-7.
60. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009;123:877-84. DOI 10.1542/peds.2008-1158
61. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35. Epub 5 Feb 2009. DOI 10.1086/596757
62. Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008;6:122-74.
63. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60. Epub 8 Jan 2008. DOI 10.1086/525258
64. Varisco BM, Benner KW, Prabhakaran P. Neonatal peritoneal candidiasis successfully treated with anidulafungin add-onn therapy. Ann Pharmacother 2009;43:1907-10. Epub 13 DOI 10.1345/aph.1M350